Articles from Calyxo, Inc.

Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, announced today that Joe Catanese, Ph.D., Chief Executive Officer of Calyxo will present at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, at 8:30 AM PT in San Francisco, CA.

Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company’s CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than 20,000 patients treated to date with the CVAC System, further establishing the technology as a new standard in kidney stone care.

Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, today announced the launch of Reverse Deflection on its second-generation CVAC System—an enhancement that empowers endourologists to perform the SURE procedure using their preferred steering mode. Calyxo also shared that for the first time, 15 presentations demonstrating the safety, efficacy, and benefits of SURE using the CVAC System were featured at WCET 2025, held in Phoenix, Arizona, September 8–12. These included randomized controlled, prospective, retrospective, real-world evidence, and ex vivo studies, with five newly reported data sets.

Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, today announced the results of multiple real-world, clinical, and pre-clinical studies demonstrating the safety, efficacy, and clinical utility of the steerable ureteroscopic renal evacuation (SURE) procedure using the Company’s CVAC System. The data were presented at the American Urological Association (AUA) 2025 Annual Meeting, which took place April 26-29 in Las Vegas. In addition to the abstracts presented at the conference, Calyxo hosted a series of events aimed at educating physicians on the CVAC System, its distinctive mechanism of action, and best practices to build confidence, ensure procedural safety, and optimize outcomes.

Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, today announced that as part of its ongoing efforts to broaden access to the CVAC System, the Company will leverage the upcoming AUA2025 annual meeting to showcase new clinical data and share learnings with the urology community. The Company’s presence at AUA2025 includes at least eight abstracts and a variety of additional educational opportunities that will give physicians and patients more confidence in the CVAC System. Over 10,000 patients have been treated with the steerable ureteroscopic renal evacuation (SURE) procedure using Calyxo’s CVAC System. The second-generation CVAC System was launched at the American Urological Association (AUA) 2024 Annual Meeting and has seen swift adoption among urologists to treat kidney stones. AUA2025 is taking place April 26-29 in Las Vegas.

Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, today announced new data presented at EAU25 that further prove the safety, efficacy, and effectiveness of performing steerable ureteroscopic renal evacuation (SURE) using the CVAC System. An all-in-one kidney stone clearance solution, the CVAC System integrates three unique design features – microjet irrigation, simultaneous flow, and a large outflow lumen – that work in tandem to maximize fragment aspiration. The data from two ex-vivo studies1, 2, and one real-world study3 collectively highlight the CVAC System’s unique mechanism of action and its ability to provide superior stone clearance while maintaining safe intra-renal pressures.

Calyxo, Inc., a medical device company developing paradigm-shifting solutions for patients with kidney stones, today announced the publication of the complete 30-day outcomes from the ASPIRE (ASPiration to Improve Renal Calculi Removal Effectiveness) clinical trial in the Journal of Endourology. The positive study results demonstrate that steerable ureteroscopic renal evacuation (SURE) using Calyxo’s CVAC Aspiration System delivered significantly higher clearance of kidney stones and significantly lower residual stone volume (RSV) compared with traditional ureteroscopy (URS)1. Data from the ASPIRE study were initially reported at the American Urological Association (AUA) Annual Meeting in May 20242.

Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announces positive new study results for its CVAC System in kidney stone clearance. The new data show that healthcare consumption (HC) events including emergency department (ED) visits, hospitalization and retreatment were significantly lower after steerable ureteroscopic renal evacuation (SURE) with the CVAC System compared to ureteroscopy (URS). The new 1-year multi-center ASPIRE study results, along with other key CVAC System data, were presented at the 41st World Congress of Endourology and Uro-Technology (WCET) in Seoul, South Korea, August 12-16, 2024.

Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio.

Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback.

Calyxo, Inc., a medical device company developing next-generation treatment solutions for patients with kidney stones, has announced the closing of a $50 million Series D financing round led by Avidity Partners with significant participation from existing investors Questa Capital and CRG.

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next-generation treatment solutions, announced this week that results of a new study analyzing the safety and efficacy of the SURE procedure for large kidney stone removal utilizing the company’s CVAC Aspiration System have been published in the Journal of Endourology.

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.